SCHEMBL6760466

SCHEMBL6760466

C[Si](C)(C)CCOCn1nc(/C=C/c2ccc3c(c2)OCO3)c2ccc([AsH]c3cccc([N+](=O)[O-])c3)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 3/20 0.38
GAA P10253 2/20 0.38
ALDH1A1 P00352 4/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
PTPN1 P18031 1/20 0.35
METAP2 P50579 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
MTOR P42345 1/20 0.34
VCP P55072 1/20 0.34
MAPK1 P28482 1/20 0.34
KEAP1 Q14145 1/20 0.34
NFE2L2 Q16236 1/20 0.34
MCL1 Q07820 1/20 0.33
PKM P14618 1/20 0.33
BLM P54132 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6760468 1.00 SMN1; SMN2 (0.38) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL5247119 0.90 PTPN1 (0.41) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL5247115 0.90 PTPN1 (0.41) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL5249412 0.88 SMN1; SMN2 (0.39) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL5249416 0.88 SMN1; SMN2 (0.39) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL5247160 0.87 KDR (0.45) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL5247154 0.85 SMN1; SMN2 (0.43) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL6286068 0.80 KDM4E (0.39) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL6282634 0.80 SMN1; SMN2 (0.38) SMN1; SMN2LMNAMAPTGAAALDH1A1
SCHEMBL6492444 0.80 SMN1; SMN2 (0.37) SMN1; SMN2LMNAMAPTGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040171634-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, LLC 2004-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171634-A1 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use CDK3, BRAF, ROCK1 SMN1; SMN2 4854/4885LMNA 3648/4885MAPT 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.